Reducing Door-to-Needle Time in Acute Stroke With Pharmacist Participation
The only factor independently associated with reduction in DTN time was pharmacist at the bedside.
HealthDay News — Having a pharmacist at bedside during acute ischemic stroke is associated with significantly shorter door-to-needle (DTN) times, according to a study published recently in the Annals of Pharmacotherapy.
Megan A. Rech, PharmD, from the Loyola Medical Center in Maywood, Ill., and colleagues conducted a retrospective cohort study to examine whether pharmacist presence at bedside during acute ischemic stroke correlated with a reduction in DTN times. Data were included for 125 patients who received recombinant tissue plasminogen activator; 45 and 80 patients had and did not have a pharmacist present (PharmD and no-PharmD groups, respectively).
The researchers found that the median DTN time was significantly shorter in the PharmD group vs the no-PharmD group (48 minutes vs 73 minutes; P <.01).
Overall, 71% and 29% of patients in the PharmD and no-PharmD groups met the goal of DTN ≤60 minutes (P <.01). The only factor independently associated with reduction in DTN time was pharmacist at the bedside (β coefficient, −23.5 minutes).
"These findings support the inclusion of a stroke-competent pharmacist in the bedside response team for acute ischemic stroke patients," the authors wrote.
Rech MA, Bennnett S, Donahey E. Pharmacist participation in acute ischemic stroke decreases door-to-needle time to recombinant tissue plasminogen activator. Ann Pharmacother. 2017;51(12):1084-1089.